GlassScriptPhysician profile
Laura L Quinnette
NPI 1922458959
$13,530.61
in general payments reported to CMS, 2019-2025
57 companies · $2,901 in 2025
The $2,901 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,717 · 2022: $1,872 · 2023: $3,213 · 2024: $2,828 · 2025: $2,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,835 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,835.21 |
| Education | $106.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,573.67 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,407.81 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,240.77 | 2021-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $1,069.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $781.29 | 2021-2025 | |
| Amgen INC. | $752.65 | 2021-2025 | Repatha, Evenity, Otezla |
| Glaxosmithkline, LLC. | $538.67 | 2021-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $520.40 | 2021-2025 | |
| Pfizer INC. | $517.16 | 2021-2025 | |
| Astellas Pharma US INC | $452.89 | 2021-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $395.50 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $384.78 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $256.72 | 2021-2025 | Verquvo, Belsomra, Capvaxive |
| Esperion Therapeutics, INC. | $246.75 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $233.16 | 2021-2025 | Xifaxan |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Quinnette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.